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Pseudomonas aeruginosa is an opportunistic pathogen and causes a wide range of acute and chronic infections. P. aeruginosa
infections are kept in check by an eﬀective immune surveillance in the healthy host, while any imbalance or defect in the normal
immune response can manifest in disease. Invasive acute infection in the immunocompromised patients is mediated by potent
extracellular and cell bound bacterial virulence factors. Life-threatening chronic infection in cystic ﬁbrosis patients is maintained
by pathogenic variants that contribute to evade detection and clearance by the immune system. Here, we reviewed the molecular
basis of receptor-mediated recognition of P. aeruginosa and their role in initiating inﬂammation and the colonization. In addition,
the consequence of the P. aeruginosa genetic adaptation for the antibacterial defence and the maintaining of chronic infection are
discussed.
1. Pathogenesis of P. aeruginosa Pneumonia
Pseudomonas aeruginosa rarely causes infection in healthy
host although it is one of the most important agents
of nosocomial infections in diverse clinical setting. The
immunocompetent host usually oﬀers eﬀective immune
surveillance against infection by P. aeruginosa;h o w e v e r ,a n y
imbalance or defect in the normal immune response to this
opportunistic pathogen can lead to infection and manifest
in disease. The spectrum of clinical diseases caused by P.
aeruginosa in humans ranges from invasive acute infections
as in patients who are mechanically ventilated, individ-
uals who are immunocompromised, and patients with
malignancies or HIV infection, to life-threatening chronic
infections as in cystic ﬁbrosis (CF) patients. P. aeruginosa
adaptability to environments that are inhospitable to most
other microorganisms, minimal nutritional requirements,
and high resistance to antibiotics allow it to survive in
diﬀerent hosts [1].
The ﬁrst step in mounting a protective immune response
is the recognition of the bacterial pathogen by cell surface
receptors, which are located on professional phagocytes
(granulocytes and monocytes/macrophages) and dendritic
c e l l sa sw e l la sn o n i m m u n ec e l l s( Figure 1(a))[ 2]. This is
followedbytheactivationofintracellularsignallingpathways
and stimulation of inﬂammatory mediators. Subsequently,
eﬀector immune mechanisms are triggered such as neu-
trophil and macrophage activation as well as initiation of
adaptive immunity through T helper cell (Th)1 or Th2
responses. In most cases, the disease process begins with
some alteration or circumvention of normal host defenses.
In patients with damaged mucosal barriers from mechanical
ventilation, trauma or antecedent viral infection, P. aerugi-
nosa colonization of the respiratory tract is often followed
by acute pneumonia, sepsis, and death. Loss of defence
mechanism and an inappropriate immune-response in
patients who are immucompromised, particularly transplant
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Figure 1: Pseudomonas aeruginosa recognition by PRRs during acute and chronic lung infection. (a) During acute lung infection, P.
aeruginosa can invade, disseminate and lead to extensive tissue damage by means of potent array of extracellular and cell bound virulence
factors. However the immunocompetent host mounts an eﬀective immune response characterized of bacterial recognition by cell surface
receptors, which are located on immune cells as well as epithelial cells. Plasma membrane-bound TLRs (TLR2, TLR4-MD2-CD14, TLR5,
and TLR9) and cytosolic NLRs (NOD1, NOD2, and IPAF) recognise P. aeruginosa PAMPs and recruit adaptors to induce downstream
signalling cascades, which result in transcription of pro-inﬂammatory mediators and mucins. These pro-inﬂammatory mediators, including
chemokines, recruit immune cells to the lung in order to clear P. aeruginosa and resolve the infection. (b) During chronic lung infection, P.
aeruginosa,enmeshedinbioﬁlmstructures,doesnot havedirectcontact totheairways epitheliumandprobablyonlyimmunogenicbacterial
components can access to airway epithelium and immune cells in the lung. In addition, during long-term colonization, bacteria undergo a
number of genetic changes and gain the ability to evade detection and clearance by the immune system, thus surviving in the host. The loss
or modiﬁcation of several PAMPs (ﬂagellin, LPS, and PGN) lead to reduced recognition by TLRs and NLRs although components of the
alginatecapsulecanstillberecognizedbothbyTLR2andTLR4.TheinadequateimmuneresponsemayexplainthechroniccolonizationofP.
aeruginosa strains. NOD, Nucleotide-binding oligomerization domain; TLR, Toll-like receptor; NLR, Nod-like receptor; IPAF, ICE-protease
activating factor; MyD88, myeloid diﬀerentiation primary response protein; CFTR, cystic ﬁbrosis transmembrane conductance regulator.
and with HIV are important risk factors for P. aeruginosa
infection.
In CF, generalized immune deﬁciency and speciﬁc
abnormalities in acquired immunity are highly unlikely,
since systemic infection is not characteristic of this disease
(Figure 1(b)). In fact, sepsis due to P. aeruginosa,e v e na f t e r
decades of lung infection, is rare, presumably due to eﬀective
humoral immunity. More likely, the disease represents a
failure of local airway defense. It has been suggested that
bacteria adhere more readily to CF airway epithelial cells
due to enhanced expression of the cell surface ganglioside
asialoGM1, promoting infection [3]. Paradoxically, it has
also been proposed that cystic ﬁbrosis transmembrane
conductance regulator (CFTR) serves as a bacterial receptor
and that its absence leads to failure to internalize and kill
bacteria [4, 5]. Furthermore, an abnormal accumulation of
ceramide in the lungs of CF mice and in epithelial cells from
CF patients has been shown to result in an increased death
rate of respiratory epithelial cells and DNA deposits on the
respiratory epithelium, which facilitate bacterial adherence
[6].
Defects in antimicrobial activity of airway ﬂuid [7], in
neutrophil phagocytosis [8] or excessive neutrophil extracel-
lular traps (NETs) formation [9] likely occur in the inﬂamed
CF airway environment but are unlikely to be the primary
defect. The respiratory tract pathophysiology in CF princi-
pally results from the inability to secrete Cl− and regulate
Na+ absorption, which causes relative dehydration of the
airway surface, depleting the periciliary layer and causing
accumulation of hyperviscous mucus that cannot be cleared
by mucociliary clearance or cough [10]. Mucus plaques
and plugs serve as a nidus for intra-luminal infection [11].
Bacteria resident within the thickened luminal mucus may
evade chemical antimicrobial factors and phagocytes [12].
Complex bacterial evolution and host adaptation occur in
the chronically infected airway, which is likely unique in CF
due to the constant and severe degree of mucus dehydration
and impaired mucus clearance. Bacterial colonies exhibiting
bioﬁlm-like properties may develop, which are diﬃcult or
impossible to eradicate. The continuous presence of bacteria
and the accompanying intense inﬂammation ultimately
remodel the airway wall, causing the ubiquitous mucous
secretory cell hyperplasia and metaplasia, submucosal gland
enlargement, hypertrophy of the bronchial circulation, ecta-
sis of bronchi and bronchioles, and variable parenchymal
cyst formation, sometimes progressing to cavitary disease,
with adjacent ﬁbrosis and pleural involvement [13].
ThepathogenesisofP. aeruginosa infectionsappearstobe
complex and multifactorial. The conditions present in acute
infections force pathogens to injure or kill the host, withJournal of Biomedicine and Biotechnology 3
multiorgan failure sometimes occurring in hours or days.
In contrast, chronic infections occur without acute injury
and in the presence of bioﬁlm structures—a population of
microorganisms that aggregates on a matrix—that develop
over days or weeks, and bacterial genetic variants may
grow in the bioﬁlms. A potent array of P. aeruginosa
extracellular and cell bound virulence factors are critical for
the initial colonization phase of infection and then invasion,
dissemination, and extensive tissue damage [14]. Flagella
and pili, the motile surface appendages of P. aeruginosa,
are responsible for bacterial motility, progression towards
epithelial contact and dissemination throughout the host
organism. These appendages also act as initial tethers in
facilitating bacteria to epithelial cell contact by binding to
the cell surface receptors. Additionally, lipopolysaccharide
(LPS) plays a similar role in bacterial adhesion [15]. Upon
cell contact, the type III secretion system (T3SS), a major
virulence determinant, is activated [16, 17] .T h eT 3 S Sa l l o w s
P. aeruginosa to inject secreted toxins through a syringe-
like apparatus directly into the eukaryotic cytoplasm. Four
eﬀector proteins are known: ExoY, ExoS, ExoT, and ExoU
and all participate, at varying levels, in the cytotoxicity of P.
aeruginosaleadingtoinvasionanddissemination[18].Other
virulence factors secreted via type II secretion system into
the extracellular space such as elastase, alkaline phosphatase,
exotoxin A, and phospholipase C are also liable for invasion
and dissemination by destroying the protective glycocalix of
the respiratory epithelium and exposing epithelial ligands to
P. aeruginosa and participate in cytotoxicity [19]. A similar
role has also been reported for pyoverdine and pyocyanin.
Most of these P. aeruginosa invasive functions are selected
against in CF chronic infection leading to less virulent but
more persistent phenotypes [20–22]. The steric shielding
or modiﬁcation of these exposed molecules is the most
eﬀective strategy for avoiding host’s innate recognition and
establishing persistent chronic infection [23]. In addition, in
the lung of CF patients, P. aeruginosa forms microcolonies
encapsulated by mucoid exopolysaccharide. The emergence
of mucoid variants is believed to mark the transition to the
fatal, chronic stage of the infection [24].
2. Sensingand Defence against
Pseudomonas aeruginosa
The innate immune system is the ﬁrst line of defence
against pathogens. Innate immune responses depend on a
vast array of nonclonally expressed receptors, named pattern
recognition receptors (PRRs), aimed at pathogen recogni-
tion. PRR bind to highly conserved invariant molecular
complexes called pathogens (microbe-) associated molecular
Patterns (PAMP or MAMPs), which are widespread and
conserved among microorganisms [36]. PRR binding with
PAMPs elicits a signalling response which results in a
rapid response against any encountered microorganisms,
including potential pathogens. This complexity of bindings
allows the immune system not only to tailor its response to a
speciﬁcpathogenbutalsotodiscriminatethesiteofinfection
or the microbial burden.
The best studied PRRs are Toll-like receptors (TLRs),
which are transmembrane proteins present at the cell surface
oronthemembraneofendocyticvesiclesorotherintracellu-
lar organelles [37]. The extracellular domain of TLRs is char-
acterized by leucine-rich repeats (LRRs) that are involved in
ligand binding. Ligand recognition induces homodimeriza-
tion or heterodimerization of the ectodomains, allowing the
intracellular domains to initiate signalling. The cytoplasmic
domain contains the highly conserved Toll/interleukin-1
(IL-1) receptor (TIR) domain, which interacts with various
adaptor molecules such as myeloid diﬀerentiation primary
response protein (MyD88) to elicit signalling. There are
currently 12 known mammalian TLRs; they recognize and
bind a wide variety of bacterial PAMPs, including LPS (typ-
ically recognized by TLR4 although some LPS species can
be recognized by TLR2), lipopeptides (TLR1, TLR2, TLR6),
lipoarabinomannan and lipoteichoic acid (TLR2 and other
TLRs), ﬂagellin (TLR5), and bacterial DNA (TLR9) [38].
Although the TLRs is the family of PRRs best stud-
ied another PRR family identiﬁed through homology to
plant R proteins has emerged as playing a crucial role
in host response. The PRR family of nucleotide-binding
oligomerization nomain-(NOD-) like receptor (NLR) pro-
teins includes 23 members in humans, and it is divided in
5 subfamilies according to their eﬀector domains. Several
studieshighlightedthatNLRNOD1andNOD2arekeycyto-
plasmic PRR [39, 40]. These proteins are characterized by a
N-terminal eﬀector domain, a centrally located nucleotide-
binding domain and multiple leucin-rich repeats in their
C-terminal end. While Nod1 is ubiquitous, Nod2 seems to
be more restricted to myelomonocytic and epithelial cells.
Both Nod1 and Nod2 sense peptidoglycan (PGN) motifs.
Nod1 exhibits speciﬁcity for a diaminopimelate containing
GlcNAc-MurNAc tripeptide (GM-TriDap) fragment that is
almost exclusively found in Gram-negative bacterial PGN,
while Nod2 binds muramyl dipeptide (MDP) motif that is
common to Gram-positive and Gram-negative bacteria [41,
42]. After recognition of bacterial ligands through the LRRs
domain Nod1 and Nod2 activate the Nuclear Factor κB( N F -
κB) and elicit the production of pro-inﬂammatory cytokines
[43]. Other NLR members, such as NLR1, NLR3 and Ipaf,
are involved in building a multisubunit protein complex
called inﬂammasome following PAMP and DAMP (danger-
associated molecular Patterns) detection [44]. This is a
tightly controlled process leading to the proteolytic process-
ing of procaspase-1, which in turns activate the interleukin-
1β. Inﬂammasome activation also accounts for a peculiar
type of cell death called pyroptosis characterized by mem-
brane cell lesions leading to the release of mature IL-1β [45].
P. aeruginosa stimulates pro-inﬂammatory cytokine pro-
duction [46]. P. aeruginosa expresses numerous PAMPs
(Table 1), among which LPS and ﬂagellin have been reported
to play a special role in signalling bacterial presence in
host. LPS is a glycolipid that constitutes the major portion
of the outermost membrane of Gram-negative bacteria.
LPS consists of three distinct regions: O-antigen, core, and
lipid A. Both O-antigen and core consist of polysaccharide
chains, whereas lipid A consists of fatty acid and phosphate4 Journal of Biomedicine and Biotechnology
Table 1: PRRs sensing P. aeruginosa-associated molecular patterns.
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moieties bonded to a central glucosamine dimer [47]. This
last portion of LPS molecule is recognized by TLR4, in
association with CD14 and the adaptor molecule MD2 [48,
49]. It has been reported that P. aeruginosa can vary LPS
acylation (number and structure of fatty acids) during its
biosynthesis [50, 51]. This variation results on a modiﬁed
sensingofthisPAMPfromthecognatereceptorTLR4,which
classically recognizes hexa-acylated LPS, and/or recognition
from TLR2, which can bind tetra- and penta-acylated pseu-
domonal LPS. The role of TLR2 in P. aeruginosa recognition
is widely treated in several studies. TLR2 is a “promiscuous”
member of the TLR family as it recognizes several ligands.
TLR2 has been reported to participate in recognition of
multiple P. aeruginosa components, including lipoproteins
[52], alginate [27], ﬂagellin [53], and exoenzyme S [25].
In addition to direct TLR2 activation it has been
proposed that P. aeruginosa triggers tumor necrosis factor
TNF-α production by human monocytes through slime
glycolipoprotein (slime-GLP) [29], an extracellular glycol-
ipid component, which is present at the bacterial surface
a n dp r o d u c e dd u r i n gin vivo infection by mucoid and
nonmucoid strains. P. aeruginosa slime-GLP is rich in
mannose, a sugar which is absent from the homologous LPS.
Slime-GLP can activate innate immune responses through
interaction with MR (Mannose receptors) which synergize
and complement the activity of TLRs. Following interaction
with P. aeruginosa MR activation elicits proinﬂammatory
cytokine production by stimulating NF-κBa n dM A P K .
P. aeruginosa MR activation synergizes TLR2 activity to
trigger maximum NF-κB stimulation and proinﬂammatory
cytokineproduction[54].Likewise,studiesinTLR9deﬁcient
mice demonstrated that signalling induced by this TLR plays
a role in cornea inﬂammation experimentally provoked by
P. aeruginosa [55].However,amorerecentreportidentiﬁeda
new-basedCpGmotif(whichisthenaturalagonistofTLR9),
CpG-ODNc41, in P. aeruginosa genome [56]. In human and
murine monocytes CpG-ODNc41 was nonstimulatory and
noncytotoxic and acted as an antagonist by inhibiting the
stimulatory activity of conventional CpG-DNAs.
Modiﬁcation in host sensing may switch the immune
response from an appropriate reaction to the presence of
the pathogen to a vicious circle in which inapt signalling
leads to excessive inﬂammation which exacerbates the eﬀect
of P. aeruginosa presence in the organism. Flagellin is a
protein that arranges itself in a hollow cylinder to form the
ﬁlament bacterial ﬂagellum. Indeed, P. aeruginosa is motile
viaasinglepolarﬂagellumthathasstructuralpropertiesvery
similar to those of enteric Gram-negative bacteria, with the
added structuralfeatureof being glycosylated [57].Aspeciﬁc
motif [58–60] in ﬂagellin monomer is a ligand for TLR5
and induces the expression of proinﬂammatory mediators
in monocytes, macrophages, intestinal, airway, and corneal
epithelial cells, resulting from the activation of the tran-
scription factor NF-kB and production of pro-inﬂammatory
cytokines [61]. The majority of studies focused on the
interaction of TLR activity and P. aeruginosa have been
carried out in vitro, on cellular models. However, up to
now no single TLR deﬁciency in transgenic mice seems to
aﬀect the host response to P. aeruginosa in lung infection,
which is one of the more common and serious aspect
of P. aeruginosa pathogenesis. Though controversial results
have been obtained by diﬀerent groups, common opinion
emerged that mice lacking individual TLR4, TLR2, or TLR5
are equally sensitive to lung P. aeruginosa infection [62–
64]. Likewise, the combination of TLR4 and TLR2 absence
does not impair the ability of P. aeruginosa to establish
infection albeit the defects in cytokine responses have been
recorded. Multitransgenic mice lacking TLR5 and TLR4
appear to be more sensitive to P. aeruginosa [62]. Most
of TLR signalling following bacterial sensing depends on
the MyD88 adaptor protein that leads the activation of
NF-kB and the production of pro-inﬂammatory cytokines.
Therefore, mice lacking MyD88 infected intranasally with P.
aeruginosa displayed elevated bacterial counts in lung [65]
along with reduced levels of cytokines such as TNF-α and
IL-1β.
Moreover, several studies report that P. aeruginosa is
sensed by the NLR family members. Notably, P. aeruginosa is
recognized by the Nod1 PRR following infection in HEK293
cells overexpressing this receptor [66]. Likewise by exploiting
various cell model systems, it was demonstrated that Nod1,
but not Nod2, recognizes in a diﬀerent way P. aeruginosa
PGN of clonal clinical strains isolated by airways of a patient
of CF at the initial and chronic stages of infection [30].
In contrast to TLR5, which senses extracellular ﬂagellin,
the Ipaf inﬂammasome is generally activated by cytosolic
ﬂagellin, which is suﬃcient for IPAF-dependent caspase-1
activation [67, 68]. In accordance with this issue, during
infection,P. aeruginosa isrecognizedbyIpafthroughﬂagellin
sensing[34,69].However,parallelstudiesreportedthatIpaf-
mediated inﬂammasome is also mounted by the presence of
a T3SS carried by several pathogens, including P. aeruginosa
[70]. More recently, a basal body rod component of theJournal of Biomedicine and Biotechnology 5
Table 2: Frequent mutations in P. aeruginosa virulence factors of
CF airways isolates.
Virulence factors Mutation∗ References
LPS pagL [30]
Flagella rpoN, ﬂeQ [72][ 20]
Alginate mucA [73][ 74]
Quorum sensing LasR [75][ 76]
T3SS exsA [20]
∗Only most common mutations in P. aeruginosa clinical strains are
reported.
T3SS apparatus has been identiﬁed as the T3SS-dependent
responsible for Ipaf activation. This component has been
found in Salmonella typhimurium (PrgJ), Burkholderia pseu-
domallei (BsaK), Escherichia coli (EprJ and EscI), Shigella
ﬂexneri (MxiI), and P. aeruginosa (PscI), inducing caspase-
1a c t i v a t i o n[ 71]. These rod proteins share a sequence motif
that is essential for detection by Ipaf, and that is similar to
the ﬂagellin motif recognized by the same receptor.
3. AvoidingHost Recognition in
Pseudomonas aeruginosaf and
EstablishingChronicInfection
Although the process of recognition of PAMPs is rapid
and eﬃcient, it is now clear that bacteria are able to
alter their structures in order to avoid or modulate this
immunerecognition.Thisbacterialbehaviourisclassedasan
“immuneevasionstrategy”.MostCFpatientsacquirechronic
P. aeruginosa infections by their teenage years and these res-
piratoryinfectionsareresponsibleformuchofthemorbidity
and mortality. It has been established that the majority of
P. aeruginosa strains infecting the lungs of CF patients are
acquired independently, presumably from diverse environ-
mental reservoirs. However, the long-term colonization of
the CF host is maintained by P. aeruginosa pathoadaptive
lineages, which are clonal with the initially acquired strain
and carried phenotypic variants [77]. A variety of host-
derived inﬂammatory product and environmental factors
contribute to select clonal variants in P. aeruginosa.A sa
result of inﬂammation, P. aeruginosa is exposed to high
levels of reactive oxygen species (ROS) and reactive nitrogen
species (RNS), which are generated primarily by neutrophils
as part of the host’s innate immune response. ROS and RNS
contribute to mutations that confer an adaptive advantage
to P. aeruginosa in the airway [78, 79]. Furthermore, within
the highly viscous mucus, a microaerobic/anaerobic milieu
prevails due to oxygen consumption by bacterial pathogens
or invading neutrophils. P. aeruginosa growth in oxygen
restricted environments leads to changes in the bacterial
phenotypes that facilitate chronic infection [11, 80].
Pathogenicity-adaptive mutations represent a genetic
mechanism for enhancing bacterial virulence without hor-
izontal transfer of speciﬁc virulence factors [81]. Common
mutations are consistently acquired by most CF patients as
those in regulators of alginate biosynthesis (mucA and algT)
[74] and virulence genes including in the LPS (pagL)
and muropeptide modiﬁcations [30], motility (rpoN)[ 72],
in the quorum-sensing regulator (lasR)[ 75, 76], in the
T3SS [82], in the multidrug-eﬄux pump (mexA) and in
mutator phenotypes (mutS)[ 83]( Table 2). Whole-genome
comparison between an isogenic early and late P. aeruginosa
pairrecoveredfromonepatient90monthsapartshowedthat
the late isolate accumulated 68 mutations [20]. Interestingly,
virulence factors required for the initiation of acute infec-
tions were selected against during chronic infection. This
indicates reduced virulence of the late strains with regard to
their ability to provoke acute infection and host recognition
[23, 84]. High adaptive genetic diversiﬁcation underlines the
immune evasion strategies, resulting in increasing chances
of bacterial survival in their niche, that is, in the airway
environment of CF patients. This evolutionary scenario is
similar to that of the genomes of pathogens which establish
chronic infection as Escherichia coli [85], Haemophilus
inﬂuenzae [86], or Helicobacter pylori [87].
Recent reports have showed that P. aeruginosa exploits
PAMPs modiﬁcation as a strategy to hijack genes involved
in innate immune responses and to favor survival in CF
patients[28,30].Lossofﬂagellarexpressionenablesimmune
evasion by the bacteria due to loss of engagement by
phagocyticreceptorsthatrecognizeﬂagellarcomponentsand
loss of immune activation through ﬂagellin-mediated TLR
signaling. Using a variety of in vitro, ex vivo,a n din vivo
infection models, Amiel et al. [28], showed that loss of P.
aeruginosa motility dramatically alters immune responses to
thesebacteriacomparedtothoseformotileisogenicbacterial
strains and that it is the loss of ﬂagellum-mediated motility,
but not ﬂagellum expression itself, that results in dramatic
bacterial resistance to phagocytosis by murine and human
phagocytes.Likewise,studiesintheagarbeadsmurinemodel
by using the P. aeruginosa isolates from patients with CF
demonstrated that the risk of chronic infection is increased
by the absence of pili and ﬂagella [21]. These studies provide
an explanation for the clinical observation that P. aeruginosa
isolates obtained from CF hosts often exhibit a nonmotile
phenotype [88] and explain how this phenotype can confer
a survival advantage for bacteria that modulate or lose their
motility during chronic infection.
Chemical structure of LPS and PGN were determined
for three P. aeruginosa clones isolated from airways of a
CF patient during a period of 7.5 years [30]. Lipid A, that
is variably penta-, hexa-, or hepta-acylated, was temporally
associated with diﬀerent stages of CF infection. Among
the three strains LPS lipid A diversity was observed in
the number and location of fatty-acid side chains. Early
and late mucoid P. aeruginosa strains synthesized a LPS
blend essentially composed by tetra-, penta-, and hexa-
acylated species. In contrast, the late nonmucoid strain was
constituted by homologue lipid A species which carried
hexa-acylated and hepta-acylated moieties. These ﬁndings
are in accordance with previous observations [50, 89, 90],
that P. aeruginosa synthesizes more highly acylated (hexa-
and hepta-acylated) LPS structures during adaptation to
the CF airways. Characterization of the bacterial genes that
modify lipid A revealed that the pagL gene was mutated in6 Journal of Biomedicine and Biotechnology
the strain obtained at the later stage of CF. As for the PGN,
diversity in early and late P. aeruginosa strains consisted in
diﬀerent distribution of canonical monomeric and dimeric
species. When tested in human cells including those of
CF origin, the strong inﬂammatory response induced by P.
aeruginosa LPS and PGN isolated at early stage of infection
was attenuated at late stage. Signiﬁcantly higher NF-κB
activation, IL-8 expression and production were detected
afterdirectactivationofTLR4/MD2-CD14byLPSandNod1
by PGN of early strain when compared to late strains [30].
Lipid A structures of P. aeruginosa aﬀected also the
inﬂammatory response in mice [30]. Leukocyte recruitment
in the bronchoalveolar lavage ﬂuid (BALF) of mice exposed
to diﬀerent LPS structures of clinical strains showed striking
diﬀerences in total diﬀerential cell counts. Signiﬁcant higher
recruitment of neutrophils was observed in mice exposed to
LPSfromearlystrainincomparisontothosetreatedwithlate
strains. Cytokine levels, tested in murine lung homogenates,
showed higher MIP-2 levels for mice treated with early LPS
than late LPS. Similar trends were obtained with KC and IL-
1β. The impaired ability of the host to mount an adequate
immune response could explain the ineﬀective eradication
of the infection and the resulting persistent infection of late
strains in comparison to the clonal early strain in the agar
b e a d sm o u s em o d e l[ 21].
A prominent feature of P. aeruginosa strains infecting CF
patients is the conversion to a mucoid, exopolysaccharide
alginate-overproducing phenotype. Mannuronic acid poly-
mers, the main components of the alginate capsule, induce
immunostimulation via TLR2 and TLR4 pathways [27].
However, the overproduction of alginate by P. aeruginosa
may be advantageous for the bacteria by impeding phago-
cytosis, and providing protection against reactive oxygen
species and antibiotics [91–93] .T h er e s p o n s eo fa i r w a y
epithelia to the stimuli presented by mucoid P. aeruginosa
is not pro-inﬂammatory and, hence, may not be conducive
to the eﬀective elimination of the pathogen [94]. Indeed,
in vivo studies suggest that clearance of mucoid strains
frommurinelungsisdiminishedcomparedwithnonmucoid
strains, indicating improved survival of alginate-producing
strains in the respiratory tract [95, 96]. Alginate enhances
mucin secretion by tracheal epithelial cells and may inhibit
neutrophil migration to the sites of infection. Interestingly,
the production of ﬂagellin and alginate by P. aeruginosa
are inversely regulated by the alternative sigma factor AlgT,
which is a positive regulator of mucoidy and a negative
regulator of ﬂagella mediated motility.
Among the four eﬀector proteins secreted by the T3SS,
exogenousExoShasbeendemonstratedtoactivateTLR2and
TLR4 [25], thus contributing to inﬂammatory responses.
However, it has been proposed that, following the infection
of CF patient airways, P. aeruginosa strains evolve to reduce
T3SS expression [18], or that populations of cells gradually
change from a type III protein secretion-positive phenotype
to a secretion-negative phenotype [97]. In addition, QS-
related and T3SS genes were downregulated in a mod-
iﬁed artiﬁcial-sputum medium, more closely resembling
CF sputum [98]. It has also been reported that the cyclic
AMP/Vfr-dependent signaling (CVS) pathway, responsible
for the regulation of the expression of multiple invasive
virulence factors, including T3SS, exotoxin A, protease IV,
andTFP,isdefectiveinmucAmutants[99].Alltheseﬁndings
suggest that mucoid conversion and inhibition of invasive
virulencedeterminantsmaybothconferaselectiveadvantage
to P. aeruginosa strains in the CF lung.
4. Conclusions
In conclusion, the last decade has witnessed an increase in
our understanding of the molecular mechanisms involved
in the recognition of P. aeruginosa as invading and standing
pathogen.Itisexpectedthatfutureeﬀortswilltrytoelucidate
in much more detail and precision the role of genetic
variability in the PRRs for the susceptibility to P. aeruginosa
infection and the mechanism of P. aeruginosa adaptation to
host. Research in the ﬁeld might lead to novel discoveries
and new therapies for patients at risk factors of P. aeruginosa
infection and might have an important impact on the quality
of life for patients with CF.
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